Cardiovascular Systems Inc. (NASDAQ:CSII) shares rose 5.7% during mid-day trading on Monday . The company traded as high as $24.25 and last traded at $23.88, with a volume of 884,636 shares changing hands. The stock had previously closed at $22.60.

CSII has been the topic of a number of analyst reports. Zacks Investment Research upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Monday, July 4th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target (up from $20.00) on shares of Cardiovascular Systems in a report on Wednesday, June 29th. Leerink Swann reiterated a “market perform” rating and issued a $15.00 price target (up from $13.00) on shares of Cardiovascular Systems in a report on Saturday, May 7th. Finally, Bank of America Corp. upgraded Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a report on Thursday, August 4th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $21.57.

The firm’s market cap is $781.31 million. The firm has a 50-day moving average of $20.12 and a 200 day moving average of $14.88.

Cardiovascular Systems (NASDAQ:CSII) last released its quarterly earnings data on Wednesday, August 3rd. The medical device company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The business earned $48.50 million during the quarter, compared to analyst estimates of $46.01 million. The company’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.27) earnings per share. Analysts predict that Cardiovascular Systems Inc. will post ($0.64) earnings per share for the current year.

In other Cardiovascular Systems news, SVP Paul A. Koehn sold 4,000 shares of the company’s stock in a transaction on Wednesday, August 17th. The stock was sold at an average price of $22.17, for a total transaction of $88,680.00. Following the transaction, the senior vice president now directly owns 102,652 shares in the company, valued at $2,275,794.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.